Anpheros Search · Treatment

Ketoconazole

Also known as: Ketoconazole Esteve (previously Ketoconazole HRA) · 1% ketoconazole · Anti Dandruff · Gembooxt Ketoconazole 1% Medicated Shampoos · Tagrit Antifungal Treament Ketoconazole 1%

General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).

In short

In the European Union, ketoconazole is indicated for the treatment of endogenous Cushing's syndrome in adults and adolescents above the age of 12 years. In the United States, it controls flaking, scaling and itching associated with dandruff. Ketoconazole is listed by the cited source as having an approved use for Cushing syndrome.

From: Source: European Medicines Agency (EMA), Ketoconazole Esteve (previously Ketoconazole HRA) — EPAR, 05/05/2025. © European Medicines Agency. · Data provided by the U.S. Food and Drug Administration. · Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.

AI-generated summary of the sources cited on this page, checked automatically against them. Not reviewed by a clinician; not medical advice.

Codes

RxNorm
6135 ketoconazole
EMA
EMEA/H/C/003906

Official indications

Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.

FDA (USA) Gembooxt Ketoconazole 1% Medicated Shampoos

Controls flaking, scaling and itching associated with dandruff

Data provided by the U.S. Food and Drug Administration.

Document date: 20260827 · Official document →

EMA (EU) Ketoconazole Esteve (previously Ketoconazole HRA)

Ketoconazole Esteve is indicated for the treatment of endogenous Cushing’s syndrome in adults and adolescents above the age of 12 years.

Source: European Medicines Agency (EMA), Ketoconazole Esteve (previously Ketoconazole HRA) — EPAR, 05/05/2025. © European Medicines Agency.

Document date: 05/05/2025 · Official document →

Related terms in the cited sources

Has an official indication for

In alphabetical order.

Other treatments A–Z

What people report

Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.

How these counts are made →

External resources

Questions

What is Ketoconazole approved for in the European Union?

Ketoconazole Esteve is indicated for the treatment of endogenous Cushing’s syndrome in adults and adolescents above the age of 12 years. (Source: European Medicines Agency (EMA), Ketoconazole Esteve (previously Ketoconazole HRA) — EPAR, 05/05/2025. © European Medicines Agency.)

Sources and attribution

  • Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
  • Data provided by the U.S. Food and Drug Administration.
  • Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
  • This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
  • Source: European Medicines Agency (EMA), Ketoconazole Esteve (previously Ketoconazole HRA) — EPAR, 05/05/2025. © European Medicines Agency.

Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →